🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

On Sept 26th, the #mesothelioma community wears blue to raise awareness of this rare cancer and need for increased funding to find a cure and improve access to treatment for patients with mesothelioma worldwide. #MesotheliomaAwarenessDay #Mesothelioma Mesothelioma Applied Research Foundation

Putting this out there to the twitter-verse / vision board. I want to to attend this @aacr /KCA conference in the future. (If there are any speaker cancellations, I am available). gilberto lopes Chul Kim

Motherhood in medicine indeed should be celebrated! Just reviewed some grant apps where i read an excellent grant then glanced at one of the letters of rec in passing stating: “and she’s done all this while a mom of 4(!) small boys- suddenly my score went from exceptional to OMG!

Jillian Thompson, CRNP, joins #DCLung22 on Saturday October 29 to discuss immunotherapy toxicity including early identification and optimal management of immune related adverse events. Earn CME, ANCC, ACPE credits. Full agenda, faculty and registration at medstarhealth.org/lung2022

November is Lung Cancer Awareness Month. If you have lungs, you can get lung cancer. #LungCancerAwarenessMonth #lungcancer

Estelamari Rodriguez (Dr. Estela Rodriguez), M.D., M.P.H., Associate Director of Community Outreach for #Thoracic #Oncology, discusses an increasing number of #LungCancer cases in non-smoking, younger women, and why biomarker testing is crucial for a lung #cancer diagnosis. #LCAM

MET alterations are a recurring resistance mechanism in patients with NSCLC receiving targeted therapy. #Pralsetinib and sequential MET inhibitors to overcome MET amplification resistance in a patient with RET fusion driven lung cancer - case report bit.ly/3SZFJt4

Case report Clinical Lung Cancer describes #SCLC transformation of #RET fusion-positive NSCLC after selective TKI. Histologic transformation likely under-diagnosed across driver-positive NSCLC as important mechanism of resistance and underscores need for biopsy. clinical-lung-cancer.com/article/S1525-…

Cant wait for Friday!

Who said you can’t listen to a lecture while in clinic? Taking a master class on #SCLC from Stephen V Liu, MD #CFS40 #lungcancer cancer PER lectures going on now. Tisdrey Torres, APRN, AOCNP #lcsm

📣We are hiring #AdvancedPracticeProviders for our Thoracic and GI teams in the Aventura area too. #nursepracticioners #APRN #joblisting Elisa Krill-Jackson MD Jose Lutzky, MD, FACP Apply here👇🏽

The results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer will be presented for the first time on June 6 at the 2023 ASCO Annual Meeting. The presentation at #ASCO23 is one of 10 abstracts on Tumor Treating Fields therapy. novocure.com/novocure-annou…

Leading up to #ASCO23, our clinical development and medical teams are sharing their aspirations for Tumor Treating Fields therapy and supporting patients with cancer. Are you attending ASCO? Visit us at booth 4096. bit.ly/3LyPFJh

One of the best parts of ASCO has been to see some of my dear friends! #ASCOfirsttimer! #ASCO2023

The highlight of my Monday with my dear friend Martin Dietrich, MD, PhD !! #ASCO

Love little reunions like this one with Tisdrey Torres, APRN, AOCNP Dr. Estela Rodriguez at Miami Beat of ASCO

What a great weekend in this city that feels like home with my Georgetown family! Stephen V Liu, MD Chul Kim #DCLung23

The phase 3 METIS clinical trial in brain metastases from non-small cell lung cancer following stereotactic radiosurgery met its primary endpoint. novocure.com/metis-phase-3-… #oncology #clinicaltrials

So excited to be at #ASCO ! What a gorgeous day to be here! Ready to learn and catch up with friends and colleagues!